Spencer A. Brown, PhD, director of surgical research at Cooper University in Camden, New Jersey, presented the latest results from his research on the characterization of HydraSolve lipoaspirate (fat) during the International Federation for Adipose Therapeutics and Science (IFATS) San Diego 2016 conference. HydraSolve is a liposuction device from Andrew Technologies that uses the company’s proprietary Tissue Liquefaction Technology (TLT), which combines natural saline solution with low levels of temperature and pressure to liquefy only targeted fat tissue. It is the first liposuction device FDA cleared for autologous fat transfer and is primarily used to transfer fat for breast reconstruction following breast cancer treatment.
Brown highlighted the following key findings from his research:
- HydraSolve fat demonstrates high viability levels, possibly 8% to 10% more viable than fat harvested with other methods.
- Stromal Vascular Fraction (SVF) from HydraSolve fat contains high levels of isolated adipose-derived stem cells that differentiated into additional fat cells (adipocyte), cartilage cells (chondrocytes) and bone cells (osteoblasts) when cultured.
For more information, visit www.hydrasolve.com.
